Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

This video shows how I grow rosella plants and harvest the calyx to make an amazing jam! <a href=" -~-~~-~~~-~~-~- Please ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone. | Corcept Therapeutics’ oral antiglucocorticoid plus ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.

In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

GRAND FORKS, N.D. - Rosella "Rosie" Anderson, 98, Grand Forks formerly of Michigan, N.D. died Thursday, Mar. 13, in Edgewood Grand Forks. Visitation will be held Monday, March 24, 2025 from 5 to 7 ...

Rosella Marie Ruesch, 92, of Florissant, MO, passed away peacefully on Saturday, March 1, 2025.

Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe Relacorilant plus nab-paclitaxel has the potential to become a new ...